[A23-78] Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V
Last updated 02.11.2023
Project no.:
A23-78
Commission:
Commission awarded on 31.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Kidneys and urinary system
Indication:
Adults with chronic kidney disease
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://dx.doi.org/10.60584/A23-78
| Project no. | Title | Status |
|---|---|---|
| A22-39 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-93 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-12 | Empagliflozin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-26 | Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A23-142 | Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |